Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities-A Brief Report
The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5-10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treat...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2022-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_db3db9ca2aa14fbfab7ac633574e2e93 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Maria Pokorska-Śpiewak |e author |
| 700 | 1 | 0 | |a Anna Dobrzeniecka |e author |
| 700 | 1 | 0 | |a Agnieszka Ogrodnik |e author |
| 245 | 0 | 0 | |a Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities-A Brief Report |
| 260 | |b MDPI AG, |c 2022-08-01T00:00:00Z. | ||
| 500 | |a 10.3390/idr14040061 | ||
| 500 | |a 2036-7449 | ||
| 520 | |a The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5-10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treatment. No adverse effects were reported during or after the treatment, and the compliance was good. Decisions on starting treatment in children below 6 years of age should be made individually, taking compliance into consideration. The adjustment of formulation and dosing of medication during treatment is necessary in young children. Further research with larger groups of patients is needed to confirm our findings. | ||
| 546 | |a EN | ||
| 690 | |a children | ||
| 690 | |a chronic kidney disease | ||
| 690 | |a direct acting antiviral | ||
| 690 | |a hepatitis C virus | ||
| 690 | |a sofosbuvir/ledipasvir | ||
| 690 | |a Other systems of medicine | ||
| 690 | |a RZ201-999 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Infectious Disease Reports, Vol 14, Iss 4, Pp 574-578 (2022) | |
| 787 | 0 | |n https://www.mdpi.com/2036-7449/14/4/61 | |
| 787 | 0 | |n https://doaj.org/toc/2036-7449 | |
| 856 | 4 | 1 | |u https://doaj.org/article/db3db9ca2aa14fbfab7ac633574e2e93 |z Connect to this object online. |